Nctid:
NCT00001521
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-06"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D000312", "term"=>"Adrenal Hyperplasia, Congenital"}, {"id"=>"D047808", "term"=>"Adrenogenital Syndrome"}, {"id"=>"D000308", "term"=>"Adrenocortical Hyperfunction"}, {"id"=>"D006965", "term"=>"Hyperplasia"}], "ancestors"=>[{"id"=>"D010335", "term"=>"Pathologic Processes"}, {"id"=>"D012734", "term"=>"Disorders of Sex Development"}, {"id"=>"D014564", "term"=>"Urogenital Abnormalities"}, {"id"=>"D052776", "term"=>"Female Urogenital Diseases"}, {"id"=>"D005261", "term"=>"Female Urogenital Diseases and Pregnancy Complications"}, {"id"=>"D000091642", "term"=>"Urogenital Diseases"}, {"id"=>"D052801", "term"=>"Male Urogenital Diseases"}, {"id"=>"D000013", "term"=>"Congenital Abnormalities"}, {"id"=>"D030342", "term"=>"Genetic Diseases, Inborn"}, {"id"=>"D043202", "term"=>"Steroid Metabolism, Inborn Errors"}, {"id"=>"D008661", "term"=>"Metabolism, Inborn Errors"}, {"id"=>"D008659", "term"=>"Metabolic Diseases"}, {"id"=>"D000307", "term"=>"Adrenal Gland Diseases"}, {"id"=>"D004700", "term"=>"Endocrine System Diseases"}, {"id"=>"D006058", "term"=>"Gonadal Disorders"}], "browseLeaves"=>[{"id"=>"M3664", "name"=>"Adrenal Hyperplasia, Congenital", "asFound"=>"Congenital Adrenal Hyperplasia", "relevance"=>"HIGH"}, {"id"=>"M25853", "name"=>"Adrenogenital Syndrome", "asFound"=>"Congenital Adrenal Hyperplasia", "relevance"=>"HIGH"}, {"id"=>"M10016", "name"=>"Hyperplasia", "asFound"=>"Hyperplasia", "relevance"=>"HIGH"}, {"id"=>"M16355", "name"=>"Syndrome", "relevance"=>"LOW"}, {"id"=>"M3660", "name"=>"Adrenocortical Hyperfunction", "asFound"=>"Adrenal Hyperplasia", "relevance"=>"HIGH"}, {"id"=>"M15545", "name"=>"Disorders of Sex Development", "relevance"=>"LOW"}, {"id"=>"M12", "name"=>"Congenital Abnormalities", "relevance"=>"LOW"}, {"id"=>"M17314", "name"=>"Urogenital Abnormalities", "relevance"=>"LOW"}, {"id"=>"M2875", "name"=>"Urogenital Diseases", "relevance"=>"LOW"}, {"id"=>"M27093", "name"=>"Female Urogenital Diseases", "relevance"=>"LOW"}, {"id"=>"M14127", "name"=>"Pregnancy Complications", "relevance"=>"LOW"}, {"id"=>"M8399", "name"=>"Female Urogenital Diseases and Pregnancy Complications", "relevance"=>"LOW"}, {"id"=>"M27095", "name"=>"Male Urogenital Diseases", "relevance"=>"LOW"}, {"id"=>"M23686", "name"=>"Genetic Diseases, Inborn", "relevance"=>"LOW"}, {"id"=>"M11641", "name"=>"Metabolism, Inborn Errors", "relevance"=>"LOW"}, {"id"=>"M25119", "name"=>"Steroid Metabolism, Inborn Errors", "relevance"=>"LOW"}, {"id"=>"M11639", "name"=>"Metabolic Diseases", "relevance"=>"LOW"}, {"id"=>"M3659", "name"=>"Adrenal Gland Diseases", "relevance"=>"LOW"}, {"id"=>"M7862", "name"=>"Endocrine System Diseases", "relevance"=>"LOW"}, {"id"=>"M9163", "name"=>"Gonadal Disorders", "relevance"=>"LOW"}, {"id"=>"T27", "name"=>"21-hydroxylase Deficiency", "asFound"=>"Congenital Adrenal Hyperplasia", "relevance"=>"HIGH"}, {"id"=>"T1457", "name"=>"Congenital Adrenal Hyperplasia", "asFound"=>"Congenital Adrenal Hyperplasia", "relevance"=>"HIGH"}, {"id"=>"T2879", "name"=>"Hyperadrenalism", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Urinary Tract, Sexual Organs, and Pregnancy Conditions", "abbrev"=>"BXS"}, {"name"=>"Diseases and Abnormalities at or Before Birth", "abbrev"=>"BC16"}, {"name"=>"Nutritional and Metabolic Diseases", "abbrev"=>"BC18"}, {"name"=>"Gland and Hormone Related Diseases", "abbrev"=>"BC19"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Symptoms and General Pathology", "abbrev"=>"BC23"}, {"name"=>"Rare Diseases", "abbrev"=>"Rare"}]}, "interventionBrowseModule"=>{"meshes"=>[{"id"=>"D006854", "term"=>"Hydrocortisone"}, {"id"=>"D005438", "term"=>"Fludrocortisone"}, {"id"=>"D000077289", "term"=>"Letrozole"}, {"id"=>"D005485", "term"=>"Flutamide"}], "ancestors"=>[{"id"=>"D000970", "term"=>"Antineoplastic Agents"}, {"id"=>"D047072", "term"=>"Aromatase Inhibitors"}, {"id"=>"D065088", "term"=>"Steroid Synthesis Inhibitors"}, {"id"=>"D004791", "term"=>"Enzyme Inhibitors"}, {"id"=>"D045504", "term"=>"Molecular Mechanisms of Pharmacological Action"}, {"id"=>"D004965", "term"=>"Estrogen Antagonists"}, {"id"=>"D006727", "term"=>"Hormone Antagonists"}, {"id"=>"D006730", "term"=>"Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id"=>"D045505", "term"=>"Physiological Effects of Drugs"}, {"id"=>"D000893", "term"=>"Anti-Inflammatory Agents"}, {"id"=>"D000726", "term"=>"Androgen Antagonists"}, {"id"=>"D018931", "term"=>"Antineoplastic Agents, Hormonal"}], "browseLeaves"=>[{"id"=>"M16509", "name"=>"Testosterone", "relevance"=>"LOW"}, {"id"=>"M4059", "name"=>"Androgens", "relevance"=>"LOW"}, {"id"=>"M4057", "name"=>"Androgen Antagonists", "relevance"=>"LOW"}, {"id"=>"M7992", "name"=>"Epinephrine", "relevance"=>"LOW"}, {"id"=>"M30371", "name"=>"Racepinephrine", "relevance"=>"LOW"}, {"id"=>"M211043", "name"=>"Epinephryl borate", "relevance"=>"LOW"}, {"id"=>"M8612", "name"=>"Flutamide", "asFound"=>"Zolpidem", "relevance"=>"HIGH"}, {"id"=>"M8108", "name"=>"Estradiol", "relevance"=>"LOW"}, {"id"=>"M1743", "name"=>"Letrozole", "asFound"=>"Help", "relevance"=>"HIGH"}, {"id"=>"M8116", "name"=>"Estrogens", "relevance"=>"LOW"}, {"id"=>"M8566", "name"=>"Fludrocortisone", "asFound"=>"Bran", "relevance"=>"HIGH"}, {"id"=>"M9912", "name"=>"Hydrocortisone", "asFound"=>"Monoclonal", "relevance"=>"HIGH"}, {"id"=>"M266279", "name"=>"Estradiol 17 beta-cypionate", "relevance"=>"LOW"}, {"id"=>"M266280", "name"=>"Estradiol 3-benzoate", "relevance"=>"LOW"}, {"id"=>"M234941", "name"=>"Polyestradiol phosphate", "relevance"=>"LOW"}, {"id"=>"M25769", "name"=>"Aromatase Inhibitors", "relevance"=>"LOW"}, {"id"=>"M155245", "name"=>"Hydrocortisone 17-butyrate 21-propionate", "relevance"=>"LOW"}, {"id"=>"M228609", "name"=>"Hydrocortisone acetate", "relevance"=>"LOW"}, {"id"=>"M263259", "name"=>"Hydrocortisone hemisuccinate", "relevance"=>"LOW"}, {"id"=>"M28817", "name"=>"Nonsteroidal Anti-Androgens", "relevance"=>"LOW"}, {"id"=>"M16508", "name"=>"Testolactone", "relevance"=>"LOW"}, {"id"=>"M7951", "name"=>"Enzyme Inhibitors", "relevance"=>"LOW"}, {"id"=>"M8114", "name"=>"Estrogen Antagonists", "relevance"=>"LOW"}, {"id"=>"M30483", "name"=>"Estrogen Receptor Antagonists", "relevance"=>"LOW"}, {"id"=>"M9789", "name"=>"Hormones", "relevance"=>"LOW"}, {"id"=>"M9788", "name"=>"Hormone Antagonists", "relevance"=>"LOW"}, {"id"=>"M4217", "name"=>"Anti-Inflammatory Agents", "relevance"=>"LOW"}, {"id"=>"M20966", "name"=>"Antineoplastic Agents, Hormonal", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}, {"name"=>"Vasoconstrictor Agents", "abbrev"=>"VaCoAg"}, {"name"=>"Respiratory System Agents", "abbrev"=>"Resp"}, {"name"=>"Antineoplastic Agents", "abbrev"=>"ANeo"}, {"name"=>"Anti-Inflammatory Agents", "abbrev"=>"Infl"}, {"name"=>"Reproductive Control Agents", "abbrev"=>"Repr"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE4"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"RANDOMIZED", "maskingInfo"=>{"masking"=>"NONE"}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"PARALLEL"}, "enrollmentInfo"=>{"type"=>"ACTUAL", "count"=>62}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1995-06-08", "type"=>"ACTUAL"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2024-05-08", "completionDateStruct"=>{"date"=>"2024-04-01", "type"=>"ACTUAL"}, "lastUpdateSubmitDate"=>"2024-05-09", "studyFirstSubmitDate"=>"1999-11-03", "studyFirstSubmitQcDate"=>"1999-11-03", "lastUpdatePostDateStruct"=>{"date"=>"2024-05-10", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"1999-11-04", "type"=>"ESTIMATED"}, "primaryCompletionDateStruct"=>{"date"=>"2024-04-01", "type"=>"ACTUAL"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Adult height", "timeFrame"=>"at 13 for boys; 14 for girls", "description"=>"The primary outcome variable is adult height which will be expressed in SD units relative to the normal population."}], "secondaryOutcomes"=>[{"measure"=>"hormone levels (plasma, urine)", "timeFrame"=>"at study conclusion and analysis", "description"=>"hormone levels"}, {"measure"=>"Predicted adult height (Bayley-Pinneau)", "timeFrame"=>"at study conclusion and analysis", "description"=>"adult height"}, {"measure"=>"Weight velocity (SD units)", "timeFrame"=>"at study conclusion and analysis", "description"=>"body mass index, and bone density"}, {"measure"=>"Growth velocity (SD units)", "timeFrame"=>"at study conclusion and analysis", "description"=>"adult height, body mass index, and bone density"}]}, "oversightModule"=>{"isFdaRegulatedDrug"=>false, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"keywords"=>["Congenital Adrenal Hyperplasia (CAH)", "Intervention", "Children"], "conditions"=>["Congenital Adrenal Hyperplasia (CAH)"]}, "referencesModule"=>{"seeAlsoLinks"=>[{"url"=>"https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1996-CH-0033.html", "label"=>"NIH Clinical Center Detailed Web Page"}]}, "descriptionModule"=>{"briefSummary"=>"This study was developed to determine if a combination of four drugs (flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone) can normalize growth in children with congenital adrenal hyperplasia.\n\nThe study will take 60 children, boys and girls and divide them into 2 groups based on the medications given. Group one will receive the new four- drug combination. Group two will receive the standard treatment for congenital adrenal hyperplasia (hydrocortisone and fludrocortisone).\n\nThe boys in group one will take the medication until the age of 14 at which time they will stop taking the four drug combination and begin receiving the standard treatment for congenital adrenal hyperplasia. Girls in group one will take the four drug combination until the age of 13, at which time they will stop and begin receiving the standard treatment for congenital adrenal hyperplasia plus flutamide. Flutamide will be given to the girls until six months after their first menstrual period.\n\nAll of the children will be followed until they reach their final adult height. The effectiveness of the treatment will be determined by measuring the patient's adult height, body mass index, and bone density. \\<TAB\\>...", "detailedDescription"=>"To test the hypothesis that the regimen of flutamide (an antiandrogen), testolactone or letrozole (an inhibitor of androgen-to-estrogen conversion), and reduced hydrocortisone dose can normalize the growth and adult stature of children with congenital adrenal hyperplasia, and can avoid the complications of supraphysiologic glucocorticoid dosage, 60 children with this disorder will be randomized to receive either the above regimen or conventional treatment until they have reached age 13 years in a girl or age 14 in a boy. After these ages boys will receive the conventional treatment and girls will receive conventional treatment plus flutamide. In girls, flutamide will be continued until 6 months after menarche. All children will be followed until they have attained final adult height. The principal outcome measures will be adult height, body mass index, and bone density."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["CHILD", "ADULT"], "maximumAge"=>"18 years", "minimumAge"=>"2 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"* INCLUSION CRITERIA:\n\nSubjects will be boys with bone ages 2 to 13 years and girls with bone ages 2 to 11 years with classic 21-hydroxylase.\n\nSubjects must either not yet have undergone pubertal activation of the hypothalamic-pituitary-gonadal axis, or, if pubertal activation has occurred, must be receiving an LHRH agonist to suppress secondary central precocious puberty.\n\nChildren with a bone age of 1 to 2 years may enroll in the protocol for optimization of conventional therapy, but will not be randomized to a study arm until the bone age reaches 2.\n\nEXCLUSION CRITERIA:\n\nChildren who have concurrent illnesses requiring glucocorticoid treatment (such as severe asthma), or requiring drugs that markedly alter hydrocortisone metabolism (such as anticonvulsants), and children who cannot be brought into reasonable control with conventional treatment (an unusual occurrence)."}, "identificationModule"=>{"nctId"=>"NCT00001521", "briefTitle"=>"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia", "organization"=>{"class"=>"NIH", "fullName"=>"National Institutes of Health Clinical Center (CC)"}, "officialTitle"=>"An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia", "orgStudyIdInfo"=>{"id"=>"960033"}, "secondaryIdInfos"=>[{"id"=>"96-CH-0033"}]}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"Investigational 1", "description"=>"boys/flutamide, letrozole, and reduced hydrocortisone dose or conventional treatment (with hydrocortisone and fludrocortisone ) until the age of 14", "interventionNames"=>["Drug: Fludrocortisone", "Drug: Hydrocortisone", "Drug: Letrozole", "Drug: Flutamide"]}, {"type"=>"EXPERIMENTAL", "label"=>"Investigational 2", "description"=>"girls/flutamide, letrozole, and reduced hydrocortisone dose, the Letrozole will discontinue at 13 y.o. and continue flutamide until 2 years after menarche or when final height is reached, whichever occurs first", "interventionNames"=>["Drug: Hydrocortisone", "Drug: Letrozole", "Drug: Flutamide"]}], "interventions"=>[{"name"=>"Fludrocortisone", "type"=>"DRUG", "description"=>"Since hydrocortisone dosage will be reduced , some patients may develop symptoms or signs of adrenal insufficiency. Patients will continue to receive an optimal fludrocortisone dose", "armGroupLabels"=>["Investigational 1"]}, {"name"=>"Hydrocortisone", "type"=>"DRUG", "description"=>"reduced hydrocortisone dose can normalize the growth and adult stature of children with congenital adrenal hyperplasia", "armGroupLabels"=>["Investigational 1", "Investigational 2"]}, {"name"=>"Letrozole", "type"=>"DRUG", "description"=>"Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.", "armGroupLabels"=>["Investigational 1", "Investigational 2"]}, {"name"=>"Flutamide", "type"=>"DRUG", "description"=>"Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol", "armGroupLabels"=>["Investigational 1", "Investigational 2"]}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"20892", "city"=>"Bethesda", "state"=>"Maryland", "country"=>"United States", "facility"=>"National Institutes of Health Clinical Center", "geoPoint"=>{"lat"=>38.98067, "lon"=>-77.10026}}], "overallOfficials"=>[{"name"=>"Deborah P Merke, M.D.", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"}]}, "ipdSharingStatementModule"=>{"ipdSharing"=>"UNDECIDED"}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "class"=>"NIH"}, "responsibleParty"=>{"type"=>"SPONSOR"}}}}
